Methods and compositions for treating hypoglycemic disorders

Abstract

This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analogue thereof.

1 .- 19 . (canceled) 
     
     
         20 . A method of treating neonatal hyperinsulinism or reducing an incidence of hypoglycemia in a subject having neonatal hyperinsulinism comprising administering to the subject an effective amount of a peptide comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 1. 
     
     
         21 . The method of claim  1 , wherein the neonatal hyperinsulinism is a non-genetic, prolonged hyperinsulinism. 
     
     
         22 . The method of claim  1 , wherein the neonatal hyperinsulinism is a result of peri-natal stress. 
     
     
         23 . The method of claim  3 , wherein the peri-natal stress is a result of small-for-gestational-age birth weight. 
     
     
         24 . The method of claim  3 , wherein the peri-natal stress is a result of birth asphyxia. 
     
     
         25 . The method of claim  1 , wherein the peptide is administered intravenously, parenterally, orally, intraperitoneally, subcutaneously, or by a combination thereof. 
     
     
         26 . The method of claim  1 , wherein the peptide is administered subcutaneously. 
     
     
         27 . The method of claim  1 , wherein the peptide is administered intravenously. 
     
     
         28 . The method of claim  1 , wherein the peptide is administered by infusion. 
     
     
         29 . The method of claim  1 , wherein the peptide is administered using a pump. 
     
     
         30 . The method of claim  1 , wherein the subject is under 10 years of age. 
     
     
         31 . The method of claim  1 , wherein the subject is under 3 years of age. 
     
     
         32 . The method of claim  1 , wherein the peptide is administered to a subject from 2 years to 10 years of age. 
     
     
         33 . The method of claim  1 , wherein the peptide consists of the amino acid sequence set forth in SEQ ID NO: 1. 
     
     
         34 . A method of treating neonatal hyperinsulinism or reducing an incidence of hypoglycemia in a subject having neonatal hyperinsulinism comprising administering to the subject an effective amount of a peptide comprising the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10. 
     
     
         35 . The method of claim  15 , wherein the neonatal hyperinsulinism is a non-genetic, prolonged hyperinsulinism. 
     
     
         36 . The method of claim  15 , wherein the neonatal hyperinsulinism is a result of peri-natal stress. 
     
     
         37 . The method of claim  15 , wherein the peptide is administered intravenously, parenterally, orally, intraperitoneally, subcutaneously, or by a combination thereof. 
     
     
         38 . A method of treating post-prandial hypoglycemia comprising administering to the subject an effective amount of a peptide comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 1. 
     
     
         39 . The method of claim  19 , wherein the peptide is administered intravenously, parenterally, orally, intraperitoneally, subcutaneously, or by a combination thereof.